Google Play icon

No benefit in treating mildly low thyroid function in pregnancy, NIH network study finds

Share
Posted March 3, 2017

There appears to be no benefit to treating mildly low thyroid function during pregnancy, according to a study by a National Institutes of Health research network.

Markedly low thyroid function during pregnancy has long been associated with impaired fetal neurological development and increased risk for preterm birth and miscarriage. Similarly, some studies have indicated that even mildly low thyroid function (subclinical hypothyroidism) could possibly affect a newborn’s cognitive development and increase the chances for pregnancy and birth complications.

Now, a large, long-term study has found no differences in cognitive functioning among children born to mothers with subclinical hypothyroidism who were treated with medication during pregnancy and children whose mothers were not treated for the condition. The study also found no differences between the groups in rates of preterm birth, stillbirth, miscarriage and gestational diabetes.

The study, appearing in the New England Journal of Medicine, was conducted by the Maternal Fetal Medicine Units Network, a clinical research consortium funded by NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). NIH’s National Institute of Neurological Disorders and Stroke also funded the study.

“Our results do not support routine thyroid screening in pregnancy since treatment did not improve maternal or infant outcomes,” said study author Uma Reddy, M.D., of the NICHD Pregnancy and Perinatology Branch.

From October 2006 to October 2009, researchers at 15 centers in the network tested thyroid hormone levels of more than 97,000 women before the 20th week of pregnancy. Women in the study were screened for elevated levels of thyroid stimulating hormone (TSH) — an indicator of reduced thyroid function—but normal levels of the thyroid hormone thyroxine (T4). They also were screened for lower levels of T4 — another potential marker of reduced thyroid function—but normal levels of TSH.

Researchers randomly assigned 677 women with mildly elevated levels of TSH to receive treatment with the drug levothyroxine (a synthetic form of T4) or a placebo.  Additionally, 526 women with mildly low T4 levels were randomized to receive the drug or a placebo. Children born to women in all the groups underwent IQ testing and were assessed by child development specialists each year until they were 5 years of age.

Researchers found no significant differences between the treated and untreated groups in pregnancy complications, such as gestational diabetes or preeclampsia (high blood pressure during pregnancy). Among newborns, there were no differences in rates of stillbirth, death, birthweight, or respiratory problems. Similarly, there were no differences in the results of developmental assessments between the two groups of children through age five.

The study results confirm those of an earlier trial(link is external) which screened about 22,000 women and followed their infants until age 3.

Source: NIH

Featured news from related categories:

Technology Org App
Google Play icon
85,387 science & technology articles

Most Popular Articles

  1. New treatment may reverse celiac disease (October 22, 2019)
  2. "Helical Engine" Proposed by NASA Engineer could Reach 99% the Speed of Light. But could it, really? (October 17, 2019)
  3. New Class of Painkillers Offers all the Benefits of Opioids, Minus the Side Effects and Addictiveness (October 16, 2019)
  4. The World's Energy Storage Powerhouse (November 1, 2019)
  5. Plastic waste may be headed for the microwave (October 18, 2019)

Follow us

Facebook   Twitter   Pinterest   Tumblr   RSS   Newsletter via Email